Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Korea.
Department of Otorhinolaryngology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Korea.
Cancer Med. 2024 Jan;13(2):e6990. doi: 10.1002/cam4.6990.
The mechanism of hearing loss following stereotactic radiosurgery (SRS) for vestibular schwannomas (VSs) remains unclear. There is conflicting evidence regarding cochlear nerve damage by transient volume expansion of VSs after radiosurgery and radiation-induced cochlear damage. This study aimed to investigate whether there is a specific patient population that can achieve definite hearing preservation after SRS for VSs.
A total of 37 consecutive patients with sporadic unilateral intracanalicular VSs and serviceable hearing (Gardner-Roberson [G-R] class I or II) were treated with SRS from 2009 to 2023. This is a retrospective study. Survival analysis with Cox regression for hearing deterioration was performed.
The median age was 55 years old. The median tumor volume was 0.089 cm , and the median marginal dose was 12.0 Gy. Nonserviceable hearing deterioration occurred in 9 patients (24.3%), with a median onset of 11.9 months after SRS. The actuarial rates of serviceable hearing preservation were 86%, 82%, and 70% at 1, 2, and 3 years after SRS, respectively. In a multivariate analysis, only baseline pure tone average > 30 dB increased the risk of nonserviceable hearing deterioration with significant hazard ratio. There were 13 patients with petit VSs whose tumor volume was smaller than 0.05 cm , and 11 of them were treated by a 4-mm single shot with a marginal dose of 12 Gy. None of the 13 patients had nonserviceable hearing deterioration.
Petit VSs that can be treated with 4-mm single or double shots with a marginal dose of 12 Gy may achieve hearing preservation after SRS.
立体定向放射外科(SRS)治疗前庭神经鞘瘤(VSs)后听力损失的机制仍不清楚。关于放射外科治疗后 VS 短暂体积膨胀引起的耳蜗神经损伤和放射性耳蜗损伤,存在相互矛盾的证据。本研究旨在探讨是否存在特定的患者群体,他们可以在接受 SRS 治疗 VS 后获得明确的听力保留。
回顾性分析 2009 年至 2023 年期间接受 SRS 治疗的 37 例单侧前庭神经鞘瘤且听力可利用(Gardner-Roberson [G-R] 分级 I 或 II)的散发性患者。采用 Cox 回归生存分析对听力恶化进行评估。
患者的中位年龄为 55 岁。肿瘤体积的中位数为 0.089cm,边缘剂量的中位数为 12.0Gy。9 例(24.3%)患者出现听力不可用恶化,中位发病时间为 SRS 后 11.9 个月。SRS 后 1、2 和 3 年的可利用听力保留率分别为 86%、82%和 70%。多变量分析显示,仅基线纯音平均听力>30dB 增加了听力不可用恶化的风险,显著的危险比。有 13 例小前庭神经鞘瘤患者,肿瘤体积小于 0.05cm,其中 11 例采用 4mm 单次照射,边缘剂量为 12Gy。这 13 例患者均无听力不可用恶化。
体积较小的前庭神经鞘瘤,可采用 4mm 单次或双次照射,边缘剂量为 12Gy,SRS 后可能实现听力保留。